Research progress of intracameral moxifloxacin in the prevention of bacterial endophthalmitis after cataract surgery
10.3760/cma.j.cn115989-20210304-00146
- VernacularTitle:莫西沙星前房注射预防白内障术后细菌性眼内炎的研究进展
- Author:
Weijia YAN
1
;
Haiyan ZHOU
;
Hong YAN
Author Information
1. 西安市人民医院(西安市第四医院) 陕西省眼科医院 西安交通大学医学院附属广仁医院，西安 710004
- Keywords:
Injections, anterior chamber;
Endophthalmitis, bacterial;
Cataract, postoperative;
Moxifloxacin;
Cefuroxime;
Vancomycin
- From:
Chinese Journal of Experimental Ophthalmology
2022;40(5):461-465
- CountryChina
- Language:Chinese
-
Abstract:
Postoperative endophthalmitis (POE) is a serious vision-threatening complication of cataract surgery, with an incidence rate of 0.033%-0.11% in China.In recent years, numerous retrospective studies and data analyses have reported that intracameral injection of antibiotics can effectively reduce the incidence of bacterial endophthalmitis, which commonly include cefuroxime, vancomycin and moxifloxacin.Globally, due to factors such as the availability, cost-effectiveness, and types of pathogens of POE, the drug choice varies to a large extent.Adverse events caused by antibiotics in the intracameral injection often occur, including macular edema, retinal vascular leakage, and uveitis caused by overdose of cefuroxime, and complications such as hemorrhagic retinal vasculitis obliterans due to vancomycin.Moxifloxacin, as a fourth-generation fluoroquinolone, has a significant effect on the prevention of bacterial endophthalmitis.Studies in the past five years related to moxifloxacin, and the significant advantages of moxifloxacin in the prevention of bacterial endophthalmitis, drug safety, duration of intracameral drug, and cost-effectiveness were summarized in this article.
